EPHA2 and neoplasm: We hypothesized that a bispecific composed of an anti-effector (e.g., anti-LRP6) antibody and an antibody binding to a guide antigen (e.g., a tumor-associated cell surface molecule such as ALCAM, EphA2 or ICAM-1) will modulate potency and cell type selectivity of the anti-effector antibody.